| HOME >> BIOLOGY >> TECHNOLOGY |
tement
This release may contain certain ''forward-looking statements" relating to the business of China Biologic Products, Inc. and its subsidiary companies. All statements, other than statements of historical fact included herein are ''forward-looking statements," including statements regarding: the significance of the new preferential income tax rate and its effect on the Company's ability to increase its financial performance and become more competitive, and on the Company's overall production capacity, revenues and market share; the ability of the Company to achieve its commercial objectives; the business strategy, plans and objectives of the Company and its subsidiaries; and any other statements of non-historical information. These forward-looking statements are often identified by the use of forward-looking terminology such as ''believes,'' ''expects'' or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. Investors should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website ( http://www.sec.gov ). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
'/>"/>
| SOURCE China Biologic Products, Inc. Copyright©2009 PR Newswire. All rights reserved |
Related biology technology :
1. China Pharma Holdings, Inc. Announces Clinical Trials Already Underway for Candesartan
2. China-Biotics, Inc. to Present at Roth Capital Partners 21st Annual OC Growth Stock Conference
3. Syngenta Enters Into Research Collaboration With Anhui Academy, China
4. China Sky One Medical, Inc. CFO to Present at Roth Conference
5. AMDL First to Implement US & China-Based, GAAP-Certified Accounting Technology to Capitalize on Lucrative China Healthcare Market
6. China Bio-Immunity Corporation Initiates Voluntary Recalls of Rabies Vaccines
7. China-Biotics, Inc. Receives Manufacturing Certificate for New Products
8. China Biologic Products Enters into Short-Term Loan Agreement
9. China Pharma Holdings, Inc. Receives SFDA Production Approval for Tiopronin Enteric-Coated Capsules
10. American Oriental Bioengineering to Participate in the 2009 UBS Greater China Conference
11. China Sky One Medical, Inc. Qualifies for Preferential Income Tax Rate
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |